Omrix Biopharmaceuticals Inc.

Ethicon, Gmbh

Sivan Doron

Yair Pilpel

Yuri Zherdev

Ashley DeAnglis

Lior Erez

Israel Nur

Erez Ilan

Tamara Byk-Tennenbaum

Anne J Gorman

Nadav Orr

Omri Faingold

Eve Montia

James Galloway

Lior Weissman

Erez Lior

The present invention provides methods for large scale preparation of sterile stable liquid thrombin composition comprised of glycerol; stable liquid thrombin compositions; and hemostatic composition and kits. The present invention further provides hemostatic compositions comprised of liquid thrombin, glycerol and gelatin. Further provided herein is a method for the large-scale production of a sterile liquid thrombin composition comprised of glycerol.

Stable liquid thrombin compositions

The present invention is directed to methods of enhancing toxicity of a glycolytic dependent compound towards a cancerous tissue and/or organ in a subject, the method being comprised of targeting the glycolytic dependent compound to the cancerous tissue and/or organ by placing oxidized regenerated cellulose (ORC) and/or oxidized cellulose (OC) in direct connection with the cancerous tissue and/or organ, and administering the glycolytic dependent compound to the subject by a systemic route.

Method of treating a disease using a glycolytic dependent compound

Provided herein are systems for preparing and delivering fibrin sealant to a surface and methods of use thereof. In one embodiment, the system comprises: a. a quantity of a liquid mixture disposed within a container, the mixture comprising: I. fibrin or II. fibrinogen and Factor II; and b. a resin bed disposed within a vessel, the vessel capable of being in fluid communication with the container, wherein when in fluid communication, passage of the mixture through the vessel results in modification of the concentration of small molecules inhibitor(s) and/or inducer(s) within the mixture, favoring fibrin clot formation.

Device and method for preparing and administering one-component fibrin sealant

The invention relates to syringes for storing and mixing components.

Syringe assembly for storing and mixing two components

The present invention is directed to compounds, methods for stabilizing thrombin activity with a thrombin binding oligonucleotide and to stabilized thrombin. The thrombin binding oligonucleotide is capable of inhibiting thrombin activity whereby the inhibition can be reversed with an antisense oligonucleotide.

Stabilized thrombin

Provided is a method of enhancing toxicity of a glycolytic dependent compound towards a cell, tissue and/or organ e.g. a diseased cell, tissue and/or organ, the method comprises contacting Oxidized Regenerated Cellulose (ORC) and/or Oxidized Cellulose (OC); and a glycolytic dependent compound with the cell, tissue and/or organ. The ORC and/or OC; and the glycolytic dependent compound are contacted with the cell, tissue and/or organ in a non-blended form.

Provided herein is a single component sealant formulation (e.g. in a liquid form), methods for its preparation, and use. The formulation includes fibrinogen; vitamin K-dependent clotting zymogens comprising at least Factor II (FII) and Factor X (FX).

One component fibrin glue comprising zymogens

The present invention is directed to compounds useful in stabilizing thrombin activity, thrombin compositions comprising the compounds, methods of using the compounds and methods of identifying compounds capable of stabilizing thrombin activity. The compounds are preferably isolated peptides comprising or interacting with the gamma loop of thrombin.

Compounds and methods for stabilizing thrombin activity

Provided herein are stable liquid sealant formulations comprising fibrin monomers and a reversible fibrin polymerization blocking agent, methods of preparing and using the formulations.

Growing community of inventors

Moshav Arugot, Israel

Sivan Doron